Hepatic progenitor cells either derived in microfluidics or exposed to exogenous ECM stimuli showed a significantly higher potential of forming hepatic organoids that could be rapidly expanded for several passages and further differentiated into functional hepatocytes.
6630899 A2GMLT8Q items 1 apa default asc 1
Michielin, F., Giobbe, G. G., Luni, C., Hu, Q., Maroni, I., Orford, M. R., Manfredi, A., Filippo, L. D., David, A. L., Cacchiarelli, D., Coppi, P. D., Eaton, S., & Elvassore, N. (2020). The Microfluidic Environment Reveals a Hidden Role of Self-Organizing Extracellular Matrix in Hepatic Commitment and Organoid Formation of hiPSCs. Cell Reports, 33(9). https://doi.org/10.1016/j.celrep.2020.108453 Cite
Investigators demonstrated here that hypoxia significantly attenuated sensitivity of hepatocellular carcinoma (HCC) cells to sorafenib treatment and reduced its proliferation. Autophagy was observed in sorafenib-treated HCC cells in hypoxia, and inhibition of autophagy by 3-MA eliminated hypoxia-induced sorafenib resistance.
[Cell Death & Disease]
6445212 WYHRLAN9 items 1 apa default asc 1
Using genetic, proteomic and pharmacological approaches, the authors identified the aminotransferases and specifically Agxt as effectors of the suppressor function of Lkb1 in amino acid-driven gluconeogenesis.
6445212 YGXUUFKU items 1 apa default asc 1
Just, P.-A., Charawi, S., Denis, R. G. P., Savall, M., Traore, M., Foretz, M., Bastu, S., Magassa, S., Senni, N., Sohier, P., Wursmer, M., Vasseur-Cognet, M., Schmitt, A., Le Gall, M., Leduc, M., Guillonneau, F., De Bandt, J.-P., Mayeux, P., Romagnolo, B., … Perret, C. (2020). Lkb1 suppresses amino acid-driven gluconeogenesis in the liver. Nature Communications, 11(1), 6127. https://doi.org/10.1038/s41467-020-19490-6 Cite
Scientists attempted to investigate the potential role of miR-9-5p in the progression of hepatocellular carcinoma (HCC). Expression of pyruvate dehydrogenase kinase 4 and miR-9-5p was examined in HCC tissues collected from HCC patients and cell lines.
[Cancer Gene Therapy]
6445212 K3VIE7EF items 1 apa default asc 1
The authors mimicked the interaction of tumor cells with liver cells and PBMC in vitro, and compared newly secreted extracellular vesicle (EV)-associated miRNAs and protein factors with those detected in melanoma patient`s plasma EV.
Overexpression of monocyte chemotactic protein-1-induced protein 1 (MCPIP1) decreased hepatitis B virus (HBV) RNA, whereas ablating MCPIP1 in vitro enhanced HBV production. The domains responsible for RNase activity or oligomerization, were required for MCPIP1-mediated viral RNA reduction.
6630899 YGF67HGN items 1 apa default asc 1
Li, Y., Que, L., Fukano, K., Koura, M., Kitamura, K., Zheng, X., Kato, T., Aly, H. H., Watashi, K., Tsukuda, S., Aizaki, H., Watanabe, N., Sato, Y., Suzuki, T., Suzuki, H. I., Hosomichi, K., Kurachi, M., Wakae, K., & Muramatsu, M. (2020). MCPIP1 reduces HBV-RNA by targeting its epsilon structure. Scientific Reports, 10(1), 20763. https://doi.org/10.1038/s41598-020-77166-z Cite
In mouse models of human leukemia, prostate cancer and hepatitis B-induced hepatocellular carcinoma, repeated infusions of these polymer nanocarriers induced sufficient host T cells expressing tumor-specific CARs or virus-specific TCRs to cause disease regression at levels similar to bolus infusions of ex vivo engineered lymphocytes.
6630899 VCTL57EA items 1 apa default asc 1
Median Technologies announced results of a preliminary retrospective study on the evaluation of the severity of hepatic fibrosis in NASH patients using a new imaging biomarker extracted from MRI/MRE images.
6630899 nan items 1 apa default asc 1
Exelixis, Inc. announced that Takeda Pharmaceutical Company Ltd., its partner responsible for the clinical development and commercialization of CABOMETYX® in Japan, received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market CABOMETYX as a treatment for patients with unresectable hepatocellular carcinoma that has progressed after prior systemic therapy.
6630899 nan items 1 apa default asc 1
Scientists investigated the spatial heterogeneity of cancer stem cell-features with the aim of identifying the unique hepatocellular carcinoma patient subgroups amenable to adjuvant treatment.
6445212 G4WY2HA2 items 1 apa default asc 1
Krause, J., von Felden, J., Casar, C., Fründt, T. W., Galaski, J., Schmidt, C., Jung, C., Ittrich, H., Weidemann, S. A., Krech, T., Heumann, A., Li, J., Fischer, L., Sauter, G., Lohse, A. W., Wege, H., & Schulze, K. (2020). Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype. BMC Cancer, 20(1), 1130. https://doi.org/10.1186/s12885-020-07580-z Cite
In in vitro assays, NCTC1469 cells subjected to hypoxia/reoxygenation were transduced with siRNA/activator of SIRT1 or miR-182 agomir to confirm the effect of SIRT1 on NCTC1469 cell behaviors as well as the regulation of miR-182 and XBP1/NLRP3 signaling pathway.
[Molecular Therapy-Nucleic Acids]
6445212 RAHYGWYD items 1 apa default asc 1
SIRT1 Alleviates Hepatic Ischemia-Reperfusion Injury Via the miR-182-Mediated XBP1/NLRP3 Pathway: Molecular Therapy - Nucleic Acids. (n.d.). Retrieved November 26, 2020, from https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(20)30371-1 Cite